Af­ter years of ef­fort, Ac­tini­um meets pri­ma­ry end­point in piv­otal AML tri­al

Ac­tini­um has made head­way on a piv­otal read­out, and the next step is get­ting all the da­ta in­to reg­u­la­tors’ hands.

The NY-based ra­dio­ther­a­pies biotech re­vealed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER